Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Chris W. who wrote (1424)	9/18/1998 4:22:00 PM
From: Walter Morton	Respond to of 2742

Hi Chris W., Receivables is a current asset on the balance sheet and by definition of current it should only include those assets that are collectible with in twelve months. Otherwise assets would be overstated according to GAAP.

To: Chris W. who wrote (1424)	9/18/1998 5:15:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 2742

You might consider CIST as a speculation. But, as Steve keeps pointing out, the fundamentals here are compelling. Steve is not trying to supplement the bottom line with the payment from IMNX. I see him as simply, continuously, pointing out the net worth of this company. I see CIST as a value investment. We just have to be patient and wait for the fundamental value of the company to be realized by the investment community. It sure has been disappointing. But, I'm betting that, given time, this fundamentally sound investment will pay off handsomely. John de C